BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 38552564)

  • 1. Predictive value of immediate early response 5 like (IER5L) in the prognosis and immune checkpoint blockade therapy of non-small cell lung cancer patients.
    Wang N; Tan X; Cao S; Liu M
    Pathol Res Pract; 2024 Apr; 256():155270. PubMed ID: 38552564
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Chen X; He YQ; Miao TW; Yin J; Liu J; Zeng HP; Zhu Q
    Int J Gen Med; 2023; 16():5889-5908. PubMed ID: 38106972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of ALOX5 in non-small cell lung cancer: A potential therapeutic target associated with immune cell infiltration.
    Zhao Q; Sun Z; Pan Y; Jing Q; Li W; Wang C
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Mar; 48(3):311-322. PubMed ID: 37164914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic and Immunological Role of FAT Family Genes in Non-Small Cell Lung Cancer.
    Feng Z; Yin Y; Liu B; Zheng Y; Shi D; Zhang H; Qin J
    Cancer Control; 2022; 29():10732748221076682. PubMed ID: 35212236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High expression of MYEOV reflects poor prognosis in non-small cell lung cancer.
    Zhang R; Ma A
    Gene; 2021 Feb; 770():145337. PubMed ID: 33278551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of specific prognostic markers for lung squamous cell carcinoma based on tumor progression, immune infiltration, and stem index.
    Wu R; Ma R; Duan X; Zhang J; Li K; Yu L; Zhang M; Liu P; Wang C
    Front Immunol; 2023; 14():1236444. PubMed ID: 37841237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Predictive Value of PAK7 Mutation for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Cancer.
    Zeng H; Tong F; Bin Y; Peng L; Gao X; Xia X; Yi X; Dong X
    Front Immunol; 2022; 13():834142. PubMed ID: 35242138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer.
    Larsen TV; Hussmann D; Nielsen AL
    Cancer Commun (Lond); 2019 Jun; 39(1):30. PubMed ID: 31159869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pan-cancer analysis of ubiquitin-specific protease 7 and its expression changes in the carcinogenesis of scar ulcer].
    Zhang SY; Ruan JJ; Jin DM; Chen N; Xie WG; Ruan QF
    Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi; 2023 Jun; 39(6):518-526. PubMed ID: 37805766
    [No Abstract]   [Full Text] [Related]  

  • 10. Expression, Prognosis and Gene Regulation Network of NFAT Transcription Factors in Non-Small Cell Lung Cancer.
    Ma J; Du R; Huang Y; Zhong W; Gui H; Mao C; Song X; Lu J
    Pathol Oncol Res; 2021; 27():529240. PubMed ID: 34257525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of RILPL2 and its correlation with tumor immune microenvironment and glycolysis in non-small cell lung cancer.
    Chen D; Zhang H; Zhao L; Liu X; Xue S; Wu P; Jiang H
    Cell Cycle; 2023 Apr; 22(7):841-857. PubMed ID: 36536539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
    Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC.
    Sun Y; Duan J; Fang W; Wang Z; Du X; Wang X; Li C; Cai S; Zhao J; Li S; Zhang L; Bai H; Wang J
    BMC Med; 2021 Oct; 19(1):239. PubMed ID: 34615542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telomere-associated genes and telomeric lncRNAs are biomarker candidates in lung squamous cell carcinoma (LUSC).
    Storti CB; de Oliveira RA; de Carvalho M; Hasimoto EN; Cataneo DC; Cataneo AJM; De Faveri J; Vasconcelos EJR; Dos Reis PP; Cano MIN
    Exp Mol Pathol; 2020 Feb; 112():104354. PubMed ID: 31837325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation and analysis of expression, prognosis and immune infiltration of WNT gene family in non-small cell lung cancer.
    Wang J; Yang Q; Tang M; Liu W
    Front Oncol; 2022; 12():911316. PubMed ID: 35957916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of TIMELESS and RORA as key clock molecules of non-small cell lung cancer and the comprehensive analysis.
    Xian H; Li Y; Zou B; Chen Y; Yin H; Li X; Pan Y
    BMC Cancer; 2022 Jan; 22(1):107. PubMed ID: 35078435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. System analysis of
    Situ Y; Gao R; Lei L; Deng L; Xu Q; Shao Z
    Int J Biol Markers; 2022 Jun; 37(2):158-169. PubMed ID: 35254116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-cell transcriptomic sequencing data reveal aberrant DNA methylation in SMAD3 promoter region in tumor-associated fibroblasts affecting molecular mechanism of radiosensitivity in non-small cell lung cancer.
    Han F; Chen S; Zhang K; Zhang K; Wang M; Wang P
    J Transl Med; 2024 Mar; 22(1):288. PubMed ID: 38493128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Downregulation of HOXA3 in lung adenocarcinoma and its relevant molecular mechanism analysed by RT-qPCR, TCGA and in silico analysis.
    Gan BL; He RQ; Zhang Y; Wei DM; Hu XH; Chen G
    Int J Oncol; 2018 Oct; 53(4):1557-1579. PubMed ID: 30066858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive Analysis of Immune Implication and Prognostic Value of
    Zeng Y; Zhang Z; Chen H; Fan J; Yuan W; Li J; Zhou S; Liu W
    Front Oncol; 2021; 11():798425. PubMed ID: 35047409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.